Evan Dellon, MD: Increasing Biopsies for Esophagitis Diagnosis

Video

Dr. Evan Dellon said up to 8 biopsies for high risk patients could be beneficial in diagnosing different diseases impacting the esophagus.

More biopsies could result in more diagnoses of various diseases impacting the esophagus, including eosinophilic gastritis (EG) and eosinophilic duodenitis (EoD).

In data presented during the 2021 Digestive Disease Week (DDW) Virtual Meeting, a team led by Evan S. Dellon, MD, Director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, found a high detection rate of the diseases following a minimum of 8 gastric and 4 duodenal biopsies.

In the study, 88 individuals who met the symptom criteria underwent upper endoscopy with a systemic gastric and duodenal biopsy protocol, followed by a histopathologic evaluation, which included the counting of eos to determine the diagnostic yield of EG and/or EoD (EG/EoD).

Among the subjects who met diagnostic criteria for EG/EoD, there was high variation in eosinophil concentration across biopsies, with a mean of 2.6 of 8 gastric biopsies and 2.2 of 4 duodenal biopsies collected per subject meeting the thresholds for EG/EoD diagnosis.

Each additional gastric and duodenal biopsy collected during endoscopy was associated with an incremental increase in the percent of EG/EoD cases captured.

In an interview with HCPLive®, Dellon explained how the study results could be implemented into real-life clinical practice in an effort to increase the diagnosis of diseases like EG and EoD.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.